ES2663242T3 - Productos génicos expresados de forma diferencial en tumores y su utilización - Google Patents
Productos génicos expresados de forma diferencial en tumores y su utilización Download PDFInfo
- Publication number
- ES2663242T3 ES2663242T3 ES10011193T ES10011193T ES2663242T3 ES 2663242 T3 ES2663242 T3 ES 2663242T3 ES 10011193 T ES10011193 T ES 10011193T ES 10011193 T ES10011193 T ES 10011193T ES 2663242 T3 ES2663242 T3 ES 2663242T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleic acid
- tumor
- associated antigen
- tumor associated
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composición farmacéutica para su utilización en un procedimiento para el tratamiento de una enfermedad cancerosa, comprendiendo el procedimiento la reducción o la inhibición de la migración o la metástasis de células tumorales, que se identifican por la expresión de un antígeno asociado a un tumor, y comprendiendo la composición farmacéutica uno o varios componentes seleccionados de entre el grupo constituido por: (i) un antígeno asociado a un tumor o una parte del mismo, (ii) un ácido nucleico, que codifica un antígeno asociado a un tumor o una parte del mismo, (iii) un anticuerpo, que se une a un antígeno asociado a un tumor o a una parte del mismo, y (iv) un ácido nucleico antisentido, que se hibrida en condiciones rigurosas específicamente con un ácido nucleico, que codifica un antígeno asociado a un tumor, en la que la parte comprende por lo menos 6 aminoácidos consecutivos del antígeno asociado a un tumor, en la que el antígeno asociado a un tumor presenta una secuencia, que es codificada por un ácido nucleico que es seleccionado de entre el grupo constituido por: (a) un ácido nucleico, que comprende una secuencia de ácido nucleico, que es seleccionada de entre el grupo constituido por las SEC ID NO: 19-21 y 54-57, y (b) un ácido nucleico, que presenta por lo menos el 90% de identidad de secuencia con el ácido nucleico de (a).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10341812A DE10341812A1 (de) | 2003-09-10 | 2003-09-10 | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2663242T3 true ES2663242T3 (es) | 2018-04-11 |
Family
ID=34258548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10011193T Expired - Lifetime ES2663242T3 (es) | 2003-09-10 | 2004-09-10 | Productos génicos expresados de forma diferencial en tumores y su utilización |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8765389B2 (es) |
| EP (7) | EP2322544A3 (es) |
| JP (3) | JP5007123B2 (es) |
| AU (1) | AU2004272270B2 (es) |
| CA (1) | CA2538528C (es) |
| DE (1) | DE10341812A1 (es) |
| ES (1) | ES2663242T3 (es) |
| WO (1) | WO2005026205A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1795596A1 (en) * | 2005-12-08 | 2007-06-13 | Ganymed Pharmaceuticals AG | Composition and methods for therapy and diagnosis of cancer |
| EP1911851A1 (en) * | 2006-10-12 | 2008-04-16 | Ganymed Pharmaceuticals AG | Compositions and methods for therapy and diagnosis of cancer and cancer metastasis |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| EP2108701A1 (en) * | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| JP5565723B2 (ja) * | 2009-04-07 | 2014-08-06 | 学校法人北里研究所 | 抗ｄｃｄモノクローナル抗体 |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| WO2013164787A1 (en) | 2012-05-02 | 2013-11-07 | Helse Stavanger As | Assay methods for diagnosing and monitoring cancer |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| WO2015140567A1 (en) * | 2014-03-21 | 2015-09-24 | Immunocore Limited | Tumor associated antigens derived from traip |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| US11308700B2 (en) | 2020-04-06 | 2022-04-19 | Saudi Arabian Oil Company | Augmented reality visualization of underground pipelines using geospatial databases and KM markers |
| US20230321135A1 (en) * | 2020-06-08 | 2023-10-12 | Qatar Foundation For Education, Science And Community Development | Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments |
| WO2023006920A1 (en) | 2021-07-29 | 2023-02-02 | BioNTech SE | Compositions and methods for treatment of melanoma |
| WO2025264662A1 (en) | 2024-06-18 | 2025-12-26 | BioNTech SE | Compositions and methods for treatment of melanoma |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0270056A1 (en) * | 1986-12-01 | 1988-06-08 | Northwestern University | Human LDH-C 4cDNA sequences encoding antigenic regions |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| AU1726199A (en) * | 1997-12-31 | 1999-07-19 | Chiron Corporation | Metastatic cancer regulated gene |
| JP2002503465A (ja) * | 1998-02-12 | 2002-02-05 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒト受容体タンパク質 |
| US6262333B1 (en) * | 1998-06-10 | 2001-07-17 | Bayer Corporation | Human genes and gene expression products |
| WO2000012702A2 (en) * | 1998-08-31 | 2000-03-09 | Bayer Corporation | Human genes differentially expressed in colorectal cancer |
| CA2356987A1 (en) * | 1998-12-23 | 2000-06-29 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| EP1208191A4 (en) * | 1999-08-13 | 2003-12-10 | Human Genome Sciences Inc | 13 HUMANE COLONAL AND COLONAL CANCER-ASSOCIATED PROTEINS |
| CA2384713A1 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002010363A2 (en) * | 2000-07-28 | 2002-02-07 | Incyte Genomics, Inc. | Protein phosphatases |
| US20020160382A1 (en) | 2000-10-11 | 2002-10-31 | Lasek Amy W. | Genes expressed in colon cancer |
| AU2002251692A1 (en) * | 2000-12-08 | 2002-08-19 | Duke University | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| AU2002255478A1 (en) * | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| EP1222928A3 (en) * | 2001-01-16 | 2003-11-05 | Universität Zürich Institut für Medizinische Virologie | Pharmaceutical compositions for treating or preventing cancer, especially melanoma |
| WO2002081638A2 (en) * | 2001-04-06 | 2002-10-17 | Origene Technologies, Inc | Prostate cancer expression profiles |
| WO2003004989A2 (en) * | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| DE10211088A1 (de) | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2005052182A2 (en) | 2003-11-26 | 2005-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method of analyzing plasma membrane protein content of cells |
-
2003
- 2003-09-10 DE DE10341812A patent/DE10341812A1/de not_active Withdrawn
-
2004
- 2004-09-10 US US10/570,957 patent/US8765389B2/en active Active
- 2004-09-10 CA CA2538528A patent/CA2538528C/en not_active Expired - Lifetime
- 2004-09-10 WO PCT/EP2004/010164 patent/WO2005026205A2/de not_active Ceased
- 2004-09-10 EP EP10011194A patent/EP2322544A3/de not_active Withdrawn
- 2004-09-10 AU AU2004272270A patent/AU2004272270B2/en not_active Expired
- 2004-09-10 EP EP10011192A patent/EP2314613A3/de not_active Withdrawn
- 2004-09-10 EP EP04765088A patent/EP1664103A2/de not_active Withdrawn
- 2004-09-10 EP EP10011191A patent/EP2336157A3/de not_active Withdrawn
- 2004-09-10 JP JP2006525779A patent/JP5007123B2/ja not_active Expired - Lifetime
- 2004-09-10 EP EP10011193.9A patent/EP2327721B1/de not_active Expired - Lifetime
- 2004-09-10 EP EP16176546.6A patent/EP3095791B1/de not_active Expired - Lifetime
- 2004-09-10 EP EP10011190A patent/EP2336156A3/de not_active Withdrawn
- 2004-09-10 ES ES10011193T patent/ES2663242T3/es not_active Expired - Lifetime
-
2011
- 2011-09-20 JP JP2011205112A patent/JP2012050441A/ja active Pending
-
2012
- 2012-07-10 JP JP2012154564A patent/JP5711698B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP2336156A3 (de) | 2011-11-16 |
| CA2538528C (en) | 2020-03-10 |
| WO2005026205A3 (de) | 2005-07-07 |
| EP2336157A3 (de) | 2011-11-16 |
| WO2005026205A2 (de) | 2005-03-24 |
| JP2013009673A (ja) | 2013-01-17 |
| US8765389B2 (en) | 2014-07-01 |
| AU2004272270A1 (en) | 2005-03-24 |
| EP1664103A2 (de) | 2006-06-07 |
| DE10341812A1 (de) | 2005-04-07 |
| EP2336157A2 (de) | 2011-06-22 |
| JP5711698B2 (ja) | 2015-05-07 |
| JP2012050441A (ja) | 2012-03-15 |
| EP3095791B1 (de) | 2020-06-10 |
| CA2538528A1 (en) | 2005-03-24 |
| EP2327721B1 (de) | 2017-12-27 |
| EP2322544A2 (de) | 2011-05-18 |
| EP2327721A2 (de) | 2011-06-01 |
| JP2007526759A (ja) | 2007-09-20 |
| EP3095791A1 (de) | 2016-11-23 |
| US20100203040A1 (en) | 2010-08-12 |
| EP2327721A3 (de) | 2011-09-21 |
| EP2336156A2 (de) | 2011-06-22 |
| EP2314613A3 (de) | 2011-11-16 |
| AU2004272270B2 (en) | 2011-07-21 |
| JP5007123B2 (ja) | 2012-08-22 |
| EP2314613A2 (de) | 2011-04-27 |
| EP2322544A3 (de) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2663242T3 (es) | Productos génicos expresados de forma diferencial en tumores y su utilización | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| AR110101A1 (es) | Miembros de unión (2) | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| NZ595896A (en) | Genetic products differentially expressed in tumors and the use thereof | |
| ES2675375T3 (es) | Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer | |
| ATE432983T1 (de) | Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden | |
| KR960705850A (ko) | 사람 쿠니즈형 프로테아제 저해인자(human kunitz-type protease inhibitors) | |
| AR047347A1 (es) | Miembros de la familia cry9 de bacillus | |
| AR036160A1 (es) | Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1 | |
| CO5601037A2 (es) | Anticuerpos anti-a beta y sus usos | |
| RU2007136026A (ru) | Варианты ил-21 | |
| AR093186A1 (es) | Proteinas de union al antigeno cd27l | |
| DE502005009602D1 (de) | Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie | |
| CL2019003409A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| JP2021525549A5 (es) | ||
| US9976146B2 (en) | Aptamer targeting MAGE-A3 peptide and uses thereof | |
| MX2022005704A (es) | Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b. | |
| DK1481990T3 (da) | A33-beslægtede antigener og deres farmakologiske anvendelser | |
| JP2019537562A5 (es) | ||
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
| EP1536006A4 (en) | CANCER-ANIMALS AND THEIR USE | |
| ATE547523T1 (de) | Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden |